Andy Suter – CEO, A. Vogel
A. Vogel CEO Dr Andy Suter outlines the Swiss herbal medicine market leader’s expansion in recent years, why it is prioritising R&D more than…
Tagged with pharmaceuticals
Susanne Caspar – CEO, Linnea
Susanne Caspar, CEO at Swiss natural API producer Linnea, talks about her first few months in the company, the pharmaceutical industry’s growing…
Georg Boonen – CEO, Max Zeller
Georg Boonen, CEO of Switzerland’s leading phytopharmaceutical player Max Zeller, discusses the company’s expanded market position at home and…
Jan Børge Jakobsen – MD, Bayer Norway
Jan Børge Jakobsen, managing director of Bayer Norway, shares how he came to lead Bayer’s Norwegian affiliate after 30 years within the Norwegian…
Damaso Molero – General Manager, 3P Biopharmaceuticals,…
Damaso Molero, general manager of 3P Biopharmaceuticals, a leading Spanish CDMO, highlights the growth of the company and the need to continuously…
Pioneering cannabis for children’s treatments
Founded in 1998, GW Pharmaceuticals is a true pioneer in cannabinoid medicines and the only pharmaceutical company with a license to cultivate…
Interview: Jaiveer Singh – CEO, Mint Pharmaceuticals,…
Jaiveer Singh, CEO of Mint Pharmaceuticals explains the company’s business model and how it fits the characteristics of the Canadian market on the…
Interview: Ian Jacobson – CEO, Juno Pharmaceuticals, Canada
Ian Jacobson, CEO of Juno Pharmaceuticals, presents the company’s business model of in-licensing and repurposing generic products. He highlights the…
Interview: John London – CEO, Nuvo Pharmaceuticals, Canada
John London, CEO at Nuvo Pharmaceuticals Inc., explains how he and his partners turned the Canadian company from insolvency into a profitable…
Interview: Chin Chun Lin – Chairman, Taiwan Leader Biotech…
Chin Chun Lin, chairman of Taiwan Leader Biotech Corp., discusses the importance of herbal medicine for preventive healthcare, and shares valuable…
Interview: Peter Gmünder – CEO, Bioforce AG, Switzerland
With a recent clinical trial showing one of Bioforce’s Echinacea products to be non-inferior to the gold standard allopathic treatment Tamiflu, CEO…
Optimism for the Pharma Industry in 2017
Do phenomenons such as Brexit and the Trump election victory mean trouble for the pharma industry or are you more optimistic? Take the PharmaBoardroom…
